首页> 美国卫生研究院文献>AAPS PharmSciTech >Formation of Itraconazole–Succinic Acid Cocrystals by Gas Antisolvent Cocrystallization
【2h】

Formation of Itraconazole–Succinic Acid Cocrystals by Gas Antisolvent Cocrystallization

机译:气体反溶剂共结晶形成伊曲康唑-琥珀酸共晶体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cocrystals of itraconazole, an antifungal drug with poor bioavailability, and succinic acid, a water-soluble dicarboxylic acid, were formed by gas antisolvent (GAS) cocrystallization using pressurized CO2 to improve itraconazole dissolution. In this study, itraconazole and succinic acid were simultaneously dissolved in a liquid solvent, tetrahydrofuran, at ambient conditions. The solution was then pressurized with CO2, which decreased the solvating power of tetrahydrofuran and caused crystallization of itraconazole–succinic acid cocrystals. The cocrystals prepared by GAS cocrystallization were compared to those produced using a traditional liquid antisolvent, n-heptane, for crystallinity, chemical structure, thermal behavior, size and surface morphology, potential clinical relevance, and stability. Powder X-ray diffraction, Fourier transform infrared spectroscopy, differential scanning calorimetry, and scanning electron microscopy analyses showed that itraconazole–succinic acid cocrystals with physical and chemical properties similar to cocrystals produced using a traditional liquid antisolvent technique can be prepared by CO2 antisolvent cocrystallization. The dissolution profile of itraconazole was significantly enhanced through GAS cocrystallization with succinic acid, achieving over 90% dissolution in less than 2 h. The cocrystals appeared stable against thermal stress for up to 4 weeks under accelerated stability conditions, showing only moderate decreases in their degree of crystallinity but no change in their crystalline structure. This study shows the utility of an itraconazole–succinic acid cocrystal for improving itraconazole bioavailability while also demonstrating the potential for CO2 to replace traditional liquid antisolvents in cocrystal preparation, thus making cocrystal production more environmentally benign and scale-up more feasible.
机译:伊曲康唑是一种生物利用度较差的抗真菌药物,而琥珀酸是一种水溶性二元羧酸,是通过使用加压CO2进行气体反溶剂(GAS)共结晶以提高伊曲康唑的溶解度而形成的。在这项研究中,伊曲康唑和琥珀酸在环境条件下同时溶解在液体溶剂四氢呋喃中。然后用二氧化碳对溶液加压,这降低了四氢呋喃的溶剂化能力,并导致伊曲康唑-琥珀酸共晶体结晶。将GAS共结晶制得的共晶体与使用传统液体反溶剂正庚烷制得的共晶体进行了结晶度,化学结构,热行为,尺寸和表面形态,潜在的临床相关性和稳定性的比较。粉末X射线衍射,傅里叶变换红外光谱,差示扫描量热法和扫描电子显微镜分析表明,伊曲康唑-琥珀酸共晶体的物理和化学性质与使用传统液体抗溶剂技术生产的共晶体相似,可以通过CO2抗溶剂共结晶制备。通过GAS与琥珀酸共结晶,伊曲康唑的溶出度显着提高,在不到2小时的时间内达到90%以上的溶出度。在加速的稳定性条件下,共晶体在长达4周的时间内对热应力表现出稳定的状态,仅显示出其结晶度适度下降,而晶体结构却没有变化。这项研究表明,伊曲康唑-琥珀酸共晶在改善伊曲康唑生物利用度的同时,还证明了在共晶制备中二氧化碳替代传统液体抗溶剂的潜力,从而使共晶生产在环境上更有利于生产,并且规模化生产更可行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号